MX2023008986A - Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. - Google Patents

Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.

Info

Publication number
MX2023008986A
MX2023008986A MX2023008986A MX2023008986A MX2023008986A MX 2023008986 A MX2023008986 A MX 2023008986A MX 2023008986 A MX2023008986 A MX 2023008986A MX 2023008986 A MX2023008986 A MX 2023008986A MX 2023008986 A MX2023008986 A MX 2023008986A
Authority
MX
Mexico
Prior art keywords
chlamydia trachomatis
inventors
vaccine purposes
antigenic polypeptides
epitopes
Prior art date
Application number
MX2023008986A
Other languages
English (en)
Inventor
Yves Levy
Gérard Zurawski
Sandra Zurawski
Sylvain Cardinaud
Mireille Centlivre
Lydie Dieudonne
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2023008986A publication Critical patent/MX2023008986A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las Chlamydiae son patógenos bacterianos responsables de una variedad de infecciones; los inventores presentan candidatos de vacuna contra Chlamydia trachomatis; particular, los inventores identificaron epítopos específicos para ser incluidos en candidatos a vacuna, gracias al análisis in silico de la secuencia de aminoácidos de estas proteínas para mapear los epítopos MHC-I y -II predichos por el software en línea (NetMHC-4.0 y NetMHCII-2.3) y el software de predicción de unión a péptido; también fueron mapeados epítopos de células B usando el software en línea (BepiPred-2.0 y Discotope); por último, los inventores generaron algunos anticuerpos de CD40 o Langerina específicos que comprenden uno o más epítopo(s) identificado(s) de la presente invención y que son adecuados para fines de vacuna; por lo tanto, la presente invención se refiere a polipéptidos antigénicos de Chlamydia trachomatis (Ct) y a usos de los mismos con fines de vacuna.
MX2023008986A 2021-01-29 2022-01-28 Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. MX2023008986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305118 2021-01-29
PCT/EP2022/052104 WO2022162177A1 (en) 2021-01-29 2022-01-28 Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes

Publications (1)

Publication Number Publication Date
MX2023008986A true MX2023008986A (es) 2023-08-15

Family

ID=74572723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008986A MX2023008986A (es) 2021-01-29 2022-01-28 Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.

Country Status (8)

Country Link
US (1) US20240124532A1 (es)
EP (1) EP4284832A1 (es)
JP (1) JP2024504195A (es)
KR (1) KR20230135620A (es)
CN (1) CN117157320A (es)
CA (1) CA3209251A1 (es)
MX (1) MX2023008986A (es)
WO (1) WO2022162177A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059899A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific polypeptides and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU6248994A (en) 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
KR100735653B1 (ko) * 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP4413617B2 (ja) * 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
CA2526106A1 (en) * 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
CN1810970B (zh) * 2005-01-27 2011-05-18 长春华普生物技术有限公司 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
CA2602637A1 (en) * 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
JP5543785B2 (ja) 2007-02-02 2014-07-09 ベイラー リサーチ インスティテュート ヒト化ターゲティングモノクローナル抗体と複合体を形成する複数の可変抗原
AU2010222930B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
KR101548143B1 (ko) 2008-07-16 2015-08-28 베일러 리서치 인스티튜트 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
BR112012005713A2 (pt) 2009-09-14 2019-09-24 Baylor Res Institute vacinas direcionadas a célula langerhans.
RU2013110889A (ru) 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP3992210A1 (en) * 2014-01-13 2022-05-04 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
JP7038064B2 (ja) * 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
JP2022512686A (ja) * 2018-10-10 2022-02-07 プレジデント アンド フェローズ オブ ハーバード カレッジ レチンアルデヒドデヒドロゲナーゼをコードする修飾ｒｎａの使用

Also Published As

Publication number Publication date
JP2024504195A (ja) 2024-01-30
KR20230135620A (ko) 2023-09-25
WO2022162177A1 (en) 2022-08-04
US20240124532A1 (en) 2024-04-18
CA3209251A1 (en) 2022-08-04
CN117157320A (zh) 2023-12-01
EP4284832A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
Kharisma et al. Construction of epitope-based peptide vaccine against SARS-CoV-2: Immunoinformatics study
Zhang et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
MX2022014943A (es) Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
MX2011009438A (es) Anticuerpos anti-cd40 y usos de los mismos.
EA201790976A1 (ru) Терапевтические вакцины против hpv16
AU2019349036A8 (en) Immune composition, preparation method therefor, and application thereof
MX337397B (es) Vacunas anti-virales dirigidas a celulas que presentan antigeno.
MX2020010421A (es) Combinaciones de composición de vacunas inductoras de células t y usos de las mismas.
MX2023008986A (es) Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
MX2018013081A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
PH12018502293A1 (en) Humanized anti-basigin antibodies and the use thereof
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
Kłyż et al. Phage proteins are expressed on the surface of Neisseria gonorrhoeae and are potential vaccine candidates
Harpin et al. Immune response to vaccination with DNA encoding the bovine viral diarrhea virus major glycoprotein gp53 (E2)
Aparicio et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
Golshani et al. In silico design, cloning and high level expression of L7/L12-TOmp31 fusion protein of Brucella antigens
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
Delgado et al. Extracellular loops of the treponema pallidum FadL orthologs TP0856 and TP0858 elicit IgG antibodies and IgG+-specific b-cells in the rabbit model of experimental syphilis
Singh et al. Molecular characterization and computational analysis of the major outer membrane protein (ompH) gene of Pasteurella multocida P52
Nonaka et al. Triskelion structure of the Gli521 protein, involved in the gliding mechanism of Mycoplasma mobile
Jelsma et al. Preliminary mapping of non-conserved epitopes on envelope glycoprotein E2 of Bovine viral diarrhea virus type 1 and 2
MX2021000102A (es) Materiales y metodos para expresion sin celulas de concatemeros de epitopos de vacuna.
MX2020002283A (es) Vacuna recombinante contra la enteropatia proliferativa en animales.
WO2018066948A3 (ko) 다수의 에피토프로 구성된 재조합 항원 단백질 및 이의 제조방법